Meta-analysis of 40 studies: clinically or molecularly defined aggressive-variant prostate cancer was associated with shorter PFS (HR 2.72) and OS (HR 2.81) vs non-AVPC; platinum chemotherapy had higher response rates than non-platinum regimens (46% vs 19%).
Meta-analysisn = 40 studies
Pedrani et al. Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis